Antiviral Drug Targets of Single-Stranded RNA Viruses Causing Chronic Human Diseases

Dhurvas    Chandrasekaran    Dinesh; Selvaraj       Tamilarasan; Kaushik       Rajaram; Evžen       Bouřa
doi:10.2174/1389450119666190920153247
Abstract

Ribonucleic acid (RNA) viruses associated with chronic diseases in humans are major threats to public health causing high mortality globally. The high mutation rate of RNA viruses helps them to escape the immune response and also is responsible for the development of drug resistance. Chronic infections caused by human immunodeficiency virus (HIV) and hepatitis viruses (HBV and HCV) lead to acquired immunodeficiency syndrome (AIDS) and hepatocellular carcinoma respectively, which are one of the major causes of human deaths. Effective preventative measures to limit chronic and re-emerging viral infections are absolutely necessary. Each class of antiviral agents targets a specific stage in the viral life cycle and inhibits them from its development and proliferation. Most often, antiviral drugs target a specific viral protein, therefore only a few broad-spectrum drugs are available. This review will be focused on the selected viral target proteins of pathogenic viruses containing single-stranded (ss) RNA genome that causes chronic infections in humans (e.g. HIV, HCV, Flaviviruses). In the recent past, an exponential increase in the number of available three-dimensional protein structures (>150000 in Protein Data Bank), allowed us to better understand the molecular mechanism of action of protein targets and antivirals. Advancements in the in silico approaches paved the way to design and develop several novels, highly specific small-molecule inhibitors targeting the viral proteins.
Keywords: RNA viruses, chronic diseases, drug targets, inhibitors, antivirals, HIV, hepatitis, flaviviruses, protein structures.
« Previous Next »
Graphical Abstract

[1] 
De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev  2016; 29(3): 695-747.
[http://dx.doi.org/10.1128/CMR.00102-15] [PMID:  27281742] 
[2] 
McCarthy MK, Morrison TE. Persistent RNA virus infections: do PAMPS drive chronic disease? Curr Opin Virol  2017; 23: 8-15.
[http://dx.doi.org/10.1016/j.coviro.2017.01.003] [PMID:  28214732] 
[3] 
Randall RE, Griffin DE. Within host RNA virus persistence: mechanisms and consequences. Curr Opin Virol  2017; 23: 35-42.
[http://dx.doi.org/10.1016/j.coviro.2017.03.001] [PMID:  28319790] 
[4] 
Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert Opin Pharmacother  2018; 19(1): 49-64.
[http://dx.doi.org/10.1080/14656566.2017.1419185] [PMID:  29252031] 
[5] 
Zuniga EI, Macal M, Lewis GM, Harker JA. Innate and adaptive immune regulation during chronic viral infections. Annu Rev Virol  2015; 2(1): 573-97.
[http://dx.doi.org/10.1146/annurev-virology-100114-055226] [PMID:  26958929] 
[6] 
Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol  2018; 16(8) e3000003
[http://dx.doi.org/10.1371/journal.pbio.3000003] [PMID:  30102691] 
[7] 
Mason S, Devincenzo JP, Toovey S, Wu JZ, Whitley RJ. Comparison of antiviral resistance across acute and chronic viral infections. Antiviral Res  2018; 158: 103-12.
[http://dx.doi.org/10.1016/j.antiviral.2018.07.020] [PMID:  30086337] 
[8] 
Chu C, Pollock LC, Selwyn PA. HIV-associated complications: A systems-based approach. Am Fam Physician  2017; 96(3): 161-9.
[PMID:  28762691] 
[9] 
Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules  2015; 20(7): 13384-421.
[http://dx.doi.org/10.3390/molecules200713384] [PMID:  26205061] 
[10] 
van Montfort RLM, Workman P. Structure-based drug design: aiming for a perfect fit. Essays Biochem  2017; 61(5): 431-7.
[http://dx.doi.org/10.1042/EBC20170052] [PMID:  29118091] 
[11] 
Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol  2012; 10(4): 279-90.
[http://dx.doi.org/10.1038/nrmicro2747] [PMID:  22421880] 
[12] 
Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M. Nucleotide sequence of the AIDS virus, LAV. Cell  1985; 40(1): 9-17.
[http://dx.doi.org/10.1016/0092-8674(85)90303-4] [PMID:  2981635] 
[13] 
Li G, De Clercq E. HIV Genome-wide protein associations: A review of 30 years of research. Microbiol Mol Biol Rev  2016; 80(3): 679-731.
[http://dx.doi.org/10.1128/MMBR.00065-15] [PMID:  27357278] 
[14] 
Human Immunodeficiency Virus (HIV). Transfus Med Hemother  2016; 43(3): 203-22.
[http://dx.doi.org/10.1159/000445852] [PMID:  27403093] 
[15] 
Barré-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol  2013; 11(12): 877-83.
[http://dx.doi.org/10.1038/nrmicro3132] [PMID:  24162027] 
[16] 
Zhan P, Pannecouque C, De Clercq E, Liu X. Anti-HIV Drug discovery and development: Current innovations and future trends. J Med Chem  2016; 59(7): 2849-78.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00497] [PMID:  26509831] 
[17] 
Rai MA, Pannek S, Fichtenbaum CJ. Emerging reverse transcriptase inhibitors for HIV-1 infection. Expert Opin Emerg Drugs  2018; 23(2): 149-57.
[http://dx.doi.org/10.1080/14728214.2018.1474202] [PMID:  29737220] 
[18] 
Jayappa KD, Ao Z, Yao X. The HIV-1 passage from cytoplasm to nucleus: the process involving a complex exchange between the components of HIV-1 and cellular machinery to access nucleus and successful integration. Int J Biochem Mol Biol  2012; 3(1): 70-85.
[PMID:  22509482] 
[19] 
Isel C, Ehresmann C, Keith G, Ehresmann B, Marquet R. Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer). J Mol Biol  1995; 247(2): 236-50.
[http://dx.doi.org/10.1006/jmbi.1994.0136] [PMID:  7707372] 
[20] 
Rhim H, Park J, Morrow CD. Deletions in the tRNA(Lys) primer-binding site of human immunodeficiency virus type 1 identify essential regions for reverse transcription. J Virol  1991; 65(9): 4555-64.
[PMID:  1714513] 
[21] 
Larsen KP, Mathiharan YK, Kappel K, et al. Architecture of an HIV-1 reverse transcriptase initiation complex. Nature  2018; 557(7703): 118-22.
[http://dx.doi.org/10.1038/s41586-018-0055-9] [PMID:  29695867] 
[22] 
Coey AT, Larsen KP, Choi J, Barrero DJ, Puglisi JD, Puglisi EV. Dynamic interplay of RNA and protein in the human immunodeficiency virus-1 reverse transcription initiation complex. J Mol Biol  2018; 430(24): 5137-50.
[http://dx.doi.org/10.1016/j.jmb.2018.08.029] [PMID:  30201267] 
[23] 
Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science  1992; 256(5065): 1783-90.
[http://dx.doi.org/10.1126/science.1377403] [PMID:  1377403] 
[24] 
Jacobo-Molina A, Ding J, Nanni RG, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA  1993; 90(13): 6320-4.
[http://dx.doi.org/10.1073/pnas.90.13.6320] [PMID:  7687065] 
[25] 
Hu WS, Hughes SH. HIV-1 reverse transcription. Cold Spring Harb Perspect Med  2012; 2(10)a006882
[http://dx.doi.org/10.1101/cshperspect.a006882] [PMID:  23028129] 
[26] 
Das K, Martinez SE, Bauman JD, Arnold E. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol  2012; 19(2): 253-9.
[http://dx.doi.org/10.1038/nsmb.2223] [PMID:  22266819] 
[27] 
Das K, Martinez SE, DeStefano JJ, Arnold E. Structure of HIV-1 RT/dsRNA initiation complex prior to nucleotide incorporation. Proc Natl Acad Sci USA  2019; 116(15): 7308-13.
[http://dx.doi.org/10.1073/pnas.1814170116] [PMID:  30902895] 
[28] 
Yang Y, Kang D, Nguyen LA, et al. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. eLife  2018; 7: 7.
[http://dx.doi.org/10.7554/eLife.36340] [PMID:  30044217] 
[29] 
Esbjörnsson J, Månsson F, Kvist A, et al. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV  2018; S2352-3018(18): 30254-6.
[PMID:  30392769] 
[30] 
Gu WG, Zhang X, Yuan JF. Anti-HIV drug development through computational methods. AAPS J  2014; 16(4): 674-80.
[http://dx.doi.org/10.1208/s12248-014-9604-9] [PMID:  24760437] 
[31] 
Soltani A, Hashemy SI, Zahedi Avval F, et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother  2019; 109: 770-8.
[http://dx.doi.org/10.1016/j.biopha.2018.10.139] [PMID:  30551530] 
[32] 
Zanella L, Otsuki K, Marin MA, Bendet I, Vicente AC. Complete genome sequence of Central Africa human T-cell lymphotropic virus subtype 1b. J Virol  2012; 86(22): 12451.
[http://dx.doi.org/10.1128/JVI.02258-12] [PMID:  23087114] 
[33] 
Lavorgna A, Harhaj EW. Regulation of HTLV-1 tax stability, cellular trafficking and NF-κB activation by the ubiquitin-proteasome pathway. Viruses  2014; 6(10): 3925-43.
[http://dx.doi.org/10.3390/v6103925] [PMID:  25341660] 
[34] 
Marino-Merlo F, Mastino A, Grelli S, Hermine O, Bazarbachi A, Macchi B. Future perspectives on drug targeting in adult T cell leukemia-lymphoma. Front Microbiol  2018; 9: 925.
[http://dx.doi.org/10.3389/fmicb.2018.00925] [PMID:  29867836] 
[35] 
Carrillo-Infante C, Abbadessa G, Bagella L, Giordano A. Viral infections as a cause of cancer (review). Int J Oncol  2007; 30(6): 1521-8.
[http://dx.doi.org/10.3892/ijo.30.6.1521] [PMID:  17487374] 
[36] 
Jinno-Oue A, Tanaka A, Shimizu N, et al. Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1. AIDS Res Hum Retroviruses  2013; 29(3): 621-9.
[http://dx.doi.org/10.1089/aid.2012.0156] [PMID:  23033806] 
[37] 
Kuhnert M, Steuber H, Diederich WE. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir. J Med Chem  2014; 57(14): 6266-72.
[http://dx.doi.org/10.1021/jm500402c] [PMID:  25006983] 
[38] 
Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol  2016; 65(1)(Suppl.): S2-S21.
[http://dx.doi.org/10.1016/j.jhep.2016.07.035] [PMID:  27641985] 
[39] 
Pirakitikulr N, Kohlway A, Lindenbach BD, Pyle AM. The coding region of the hcv genome contains a network of regulatory rna structures. Mol Cell  2016; 62(1): 111-20.
[http://dx.doi.org/10.1016/j.molcel.2016.01.024] [PMID:  26924328] 
[40] 
Axley P, Ahmed Z, Ravi S, Singal AK, Hepatitis C. Hepatitis C virus and hepatocellular carcinoma: A Narrative Review. J Clin Transl Hepatol  2018; 6(1): 79-84.
[http://dx.doi.org/10.14218/JCTH.2017.00067] [PMID:  29607308] 
[41] 
Atoom AM, Taylor NG, Russell RS. The elusive function of the hepatitis C virus p7 protein. Virology  2014; 462-463: 377-87.
[http://dx.doi.org/10.1016/j.virol.2014.04.018] [PMID:  25001174] 
[42] 
Mitchell JK, Lemon SM, McGivern DR. How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol  2015; 14: 101-8.
[http://dx.doi.org/10.1016/j.coviro.2015.09.003] [PMID:  26426687] 
[43] 
McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B. Protease inhibitors block multiple functions of the ns3/4a protease-helicase during the hepatitis c virus life cycle. J Virol  2015; 89(10): 5362-70.
[http://dx.doi.org/10.1128/JVI.03188-14] [PMID:  25740995] 
[44] 
Meeprasert A, Hannongbua S, Rungrotmongkol T. Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus. J Chem Inf Model  2014; 54(4): 1208-17.
[http://dx.doi.org/10.1021/ci400605a] [PMID:  24689657] 
[45] 
Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population. Kidney Blood Press Res  2015; 40(3): 258-65.
[http://dx.doi.org/10.1159/000368501] [PMID:  25997572] 
[46] 
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet  2011; 378(9785): 73-85.
[http://dx.doi.org/10.1016/S0140-6736(10)61931-9] [PMID:  21511329] 
[47] 
Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol  2019; 4(2): 127-34.
[http://dx.doi.org/10.1016/S2468-1253(18)30343-1] [PMID:  30555048] 
[48] 
Heo YA, Deeks ED. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. Drugs  2018; 78(5): 577-87.
[http://dx.doi.org/10.1007/s40265-018-0895-5] [PMID:  29546556] 
[49] 
Taylor JG, Zipfel S, Ramey K, et al. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®. Bioorg Med Chem Lett  2019; 29(16): 2428-36.
[http://dx.doi.org/10.1016/j.bmcl.2019.03.037] [PMID:  31133531] 
[50] 
de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis  2017; 5: Doc08.
[PMID:  30671330] 
[51] 
Xue W, Ban Y, Liu H, Yao X. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model  2014; 54(2): 621-33.
[http://dx.doi.org/10.1021/ci400060j] [PMID:  23745769] 
[52] 
Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog  2012; 8(7)e1002832
[http://dx.doi.org/10.1371/journal.ppat.1002832] [PMID:  22910833] 
[53] 
Paixão ES, Teixeira MG, Rodrigues LC. Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases. BMJ Glob Health  2018; 3(Suppl. 1).e000530
[http://dx.doi.org/10.1136/bmjgh-2017-000530] [PMID:  29435366] 
[54] 
Boldescu V, Behnam MAM, Vasilakis N, Klein CD. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov  2017; 16(8): 565-86.
[http://dx.doi.org/10.1038/nrd.2017.33] [PMID:  28473729] 
[55] 
Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res  2013; 100(2): 500-19.
[http://dx.doi.org/10.1016/j.antiviral.2013.09.013] [PMID:  24076358] 
[56] 
Kok WM. New developments in flavivirus drug discovery. Expert Opin Drug Discov  2016; 11(5): 433-45.
[http://dx.doi.org/10.1517/17460441.2016.1160887] [PMID:  26966889] 
[57] 
Hasan SS, Sevvana M, Kuhn RJ, Rossmann MG. Structural biology of Zika virus and other flaviviruses. Nat Struct Mol Biol  2018; 25(1): 13-20.
[http://dx.doi.org/10.1038/s41594-017-0010-8] [PMID:  29323278] 
[58] 
Kaptein SJ, Neyts J. Towards antiviral therapies for treating dengue virus infections. Curr Opin Pharmacol  2016; 30: 1-7.
[http://dx.doi.org/10.1016/j.coph.2016.06.002] [PMID:  27367615] 
[59] 
Kalayanarooj S. Clinical Manifestations and Management of Dengue/DHF/DSS. Trop Med Health  2011; 39(4)(Suppl.): 83-7.
[http://dx.doi.org/10.2149/tmh.2011-S10] [PMID:  22500140] 
[60] 
White JP, Xiong S, Malvin NP, Khoury-Hanold W, Heuckeroth RO, Stappenbeck TS, et al. Intestinal dysmotility syndromes following systemic infection by flaviviruses. Cell  2018; 175(5): 1198-212. e12
[http://dx.doi.org/10.1016/j.cell.2018.08.069] 
[61] 
Skoreński M MA, Pyrć K, Sieńczyk M, Oleksyszyn J. Inhibitors compounds of the flavivirus replication process  2017; 14(1): 95.
[62] 
García LL, Padilla L, Castaño JC. Inhibitors compounds of the flavivirus replication process. Virol J  2017; 14(1): 95.
[http://dx.doi.org/10.1186/s12985-017-0761-1] [PMID:  28506240] 
[63] 
Hercík K, Kozak J, Šála M, et al. Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase. Antiviral Res  2017; 137: 131-3.
[http://dx.doi.org/10.1016/j.antiviral.2016.11.020] [PMID:  27902932] 
[64] 
Nitsche C. Strategies towards protease inhibitors for emerging flaviviruses. Adv Exp Med Biol  2018; 1062: 175-86.
[http://dx.doi.org/10.1007/978-981-10-8727-1_13] [PMID:  29845533] 
[65] 
Dubankova A, Boura E. Structure of the yellow fever NS5 protein reveals conserved drug targets shared among flaviviruses. Antiviral Res 2019. 169104536
[http://dx.doi.org/10.1016/j.antiviral.2019.104536] [PMID:  31202975] 
[66] 
Hernandez J, Hoffer L, Coutard B, et al. Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors. Eur J Med Chem  2019; 161: 323-33.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.056] [PMID:  30368131] 
[67] 
Hercik K, Brynda J, Nencka R, Boura E. Structural basis of Zika virus methyltransferase inhibition by sinefungin. Arch Virol  2017; 162(7): 2091-6.
[http://dx.doi.org/10.1007/s00705-017-3345-x] [PMID:  28357511] 
[68] 
Coutard B, Barral K, Lichière J, et al. Zika virus methyltransferase: structure and functions for drug design perspectives. J Virol  2017; 91(5): e02202-16.
[http://dx.doi.org/10.1128/JVI.02202-16] [PMID:  28031359] 
[69] 
Brecher M, Chen H, Li Z, et al. Identification and characterization of novel broad-spectrum inhibitors of the flavivirus methyltransferase. ACS Infect Dis  2015; 1(8): 340-9.
[http://dx.doi.org/10.1021/acsinfecdis.5b00070] [PMID:  26726314] 
[70] 
Kaaijk P, Luytjes W. Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination. Hum Vaccin Immunother  2018; 14(2): 337-44.
[http://dx.doi.org/10.1080/21645515.2017.1389363] [PMID:  29053401] 
[71] 
Rey FA, Stiasny K, Vaney MC, Dellarole M, Heinz FX. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep  2018; 19(2): 206-24.
[http://dx.doi.org/10.15252/embr.201745302] [PMID:  29282215] 
[72] 
Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil J. Development of vaccines against Zika virus. Lancet Infect Dis  2018; 18(7): e211-9.
[http://dx.doi.org/10.1016/S1473-3099(18)30063-X] [PMID:  29396004] 
[73] 
Garmaroudi FS, Marchant D, Hendry R, et al. Coxsackievirus B3 replication and pathogenesis. Future Microbiol  2015; 10(4): 629-53.
[http://dx.doi.org/10.2217/fmb.15.5] [PMID:  25865198] 
[74] 
Alidjinou EK, Sané F, Bertin A, Caloone D, Hober D. Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine. Antiviral Res  2015; 116: 51-4.
[http://dx.doi.org/10.1016/j.antiviral.2015.01.010] [PMID:  25655448] 
[75] 
Sin J, Mangale V, Thienphrapa W, Gottlieb RA, Feuer R. Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology  2015; 484: 288-304.
[http://dx.doi.org/10.1016/j.virol.2015.06.006] [PMID:  26142496] 
[76] 
Gruez A, Selisko B, Roberts M, et al. The crystal structure of coxsackievirus B3 RNA-dependent RNA polymerase in complex with its protein primer VPg confirms the existence of a second VPg binding site on Picornaviridae polymerases. J Virol  2008; 82(19): 9577-90.
[http://dx.doi.org/10.1128/JVI.00631-08] [PMID:  18632861] 
[77] 
Gong P, Kortus MG, Nix JC, Davis RE, Peersen OB. Structures of coxsackievirus, rhinovirus, and poliovirus polymerase elongation complexes solved by engineering RNA mediated crystal contacts. PLoS One  2013; 8(5)e60272
[http://dx.doi.org/10.1371/journal.pone.0060272] [PMID:  23667424] 
[78] 
Garmaroudi FS, Marchant D, Hendry R, et al. Coxsackievirus B3 replication and pathogenesis. Future Microbiol  2015; 10(4): 629-53.
[http://dx.doi.org/10.2217/fmb.15.5] [PMID:  25865198] 
[79] 
Campagnola G, Weygandt M, Scoggin K, Peersen O. Crystal structure of coxsackievirus B3 3Dpol highlights the functional importance of residue 5 in picornavirus polymerases. J Virol  2008; 82(19): 9458-64.
[http://dx.doi.org/10.1128/JVI.00647-08] [PMID:  18632862] 
[80] 
Karr JP, Peersen OB. ATP is an allosteric inhibitor of coxsackievirus b3 polymerase. Biochemistry  2016; 55(28): 3995-4002.
[http://dx.doi.org/10.1021/acs.biochem.6b00467] [PMID:  27319576] 
[81] 
Ulferts R, de Boer SM, van der Linden L, et al. Screening of a library of fda-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2c. Antimicrob Agents Chemother  2016; 60(5): 2627-38.
[http://dx.doi.org/10.1128/AAC.02182-15] [PMID:  26856848] 
[82] 
Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet  2015; 385(9984): 2297-307.
[http://dx.doi.org/10.1016/S0140-6736(14)60539-0] [PMID:  25576992] 
[83] 
Mejdrová I, Chalupská D, Plačková P, et al. Rational design of novel highly potent and selective phosphatidylinositol 4-kinase iiiβ (pi4kb) inhibitors as broad-spectrum antiviral agents and tools for chemical biology. J Med Chem  2017; 60(1): 100-18.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01465] [PMID:  28004945] 
[84] 
Mejdrová I, Chalupská D, Kögler M, et al. Highly selective phosphatidylinositol 4-kinase iiiβ inhibitors and structural insight into their mode of action. J Med Chem  2015; 58(9): 3767-93.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00499] [PMID:  25897704] 
[85] 
Tyor W, Harrison T. Mumps and rubella. Handb Clin Neurol  2014; 123: 591-600.
[http://dx.doi.org/10.1016/B978-0-444-53488-0.00028-6] [PMID:  25015506] 
[86] 
Fontana J, Tzeng WP, Calderita G, Fraile-Ramos A, Frey TK, Risco C. Novel replication complex architecture in rubella replicon-transfected cells. Cell Microbiol  2007; 9(4): 875-90.
[http://dx.doi.org/10.1111/j.1462-5822.2006.00837.x] [PMID:  17087733] 
[87] 
Dubé M, Rey FA, Kielian M. Rubella virus: first calcium-requiring viral fusion protein. PLoS Pathog  2014; 10(12)e1004530
[http://dx.doi.org/10.1371/journal.ppat.1004530] [PMID:  25474548] 
[88] 
Mangala Prasad V, Willows SD, Fokine A, et al. Rubella virus capsid protein structure and its role in virus assembly and infection. Proc Natl Acad Sci USA  2013; 110(50): 20105-10.
[http://dx.doi.org/10.1073/pnas.1316681110] [PMID:  24282305] 
[89] 
Mangala Prasad V, Klose T, Rossmann MG. Assembly, maturation and three-dimensional helical structure of the teratogenic rubella virus. PLoS Pathog  2017; 13(6)e1006377
[http://dx.doi.org/10.1371/journal.ppat.1006377] [PMID:  28575072] 
[90] 
Kowalzik F, Faber J, Knuf M. MMR and MMRV vaccines. Vaccine  2018; 36(36): 5402-7.
[http://dx.doi.org/10.1016/j.vaccine.2017.07.051] [PMID:  28757060] 
[91] 
Hviid A, Hansen JV, Frisch M, Melbye M. Measles, mumps, rubella vaccination and autism: A nationwide cohort study 2019.
[92] 
Petrova EK, Dmitrieva AA, Trifonova EA, Nikitin NA, Karpova OV. The key role of rubella virus glycoproteins in the formation of immune response, and perspectives on their use in the development of new recombinant vaccines. Vaccine  2016; 34(8): 1006-11.
[http://dx.doi.org/10.1016/j.vaccine.2016.01.010] [PMID:  26776468] 
[93] 
Hashiguchi T, Fukuda Y, Matsuoka R, et al. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors. Proc Natl Acad Sci USA  2018; 115(10): 2496-501.
[http://dx.doi.org/10.1073/pnas.1718957115] [PMID:  29463726] 
[94] 
Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol  2006; 4(12): 900-8.
[http://dx.doi.org/10.1038/nrmicro1550] [PMID:  17088933] 
[95] 
Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet  2003; 361(9359): 763-73.
[http://dx.doi.org/10.1016/S0140-6736(03)12661-X] [PMID:  12620751] 
[96] 
Ndungu JM, Krumm SA, Yan D, et al. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics. J Med Chem  2012; 55(9): 4220-30.
[http://dx.doi.org/10.1021/jm201699w] [PMID:  22480182] 
[97] 
Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. Nat Rev Dis Primers  2016; 2: 16049.
[http://dx.doi.org/10.1038/nrdp.2016.49] [PMID:  27411684] 
[98] 
Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol  2006; 4(12): 900-8.
[http://dx.doi.org/10.1038/nrmicro1550] [PMID:  17088933] 
[99] 
Griffin DE, Lin WH, Pan CH. Measles virus, immune control, and persistence. FEMS Microbiol Rev  2012; 36(3): 649-62.
[http://dx.doi.org/10.1111/j.1574-6976.2012.00330.x] [PMID:  22316382] 
[100] 
Plemper RK, Snyder JP. Measles control--can measles virus inhibitors make a difference? Curr Opin Investig Drugs  2009; 10(8): 811-20.
[PMID:  19649926] 
[101] 
Ohimain EI. Recent advances in the development of vaccines for Ebola virus disease. Virus Res  2016; 211: 174-85.
[http://dx.doi.org/10.1016/j.virusres.2015.10.021] [PMID:  26596227] 
[102] 
McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis  2014; 210(4): 558-66.
[http://dx.doi.org/10.1093/infdis/jiu088] [PMID:  24526742] 
[103] 
Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The pathogenesis of ebola virus disease. Annu Rev Pathol  2017; 12: 387-418.
[http://dx.doi.org/10.1146/annurev-pathol-052016-100506] [PMID:  27959626] 
[104] 
Leligdowicz A, Fischer WA II, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care  2016; 20(1): 217.
[http://dx.doi.org/10.1186/s13054-016-1325-2] [PMID:  27468829] 
[105] 
Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature  2014; 508(7496): 402-5.
[http://dx.doi.org/10.1038/nature13027] [PMID:  24590073] 
[106] 
Sissoko D, Laouenan C, Folkesson E, et al. Correction: Experimental treatment with favipiravir for ebola virus disease (the jiki trial): a historically controlled, single-arm proof-of-concept trial in guinea. PLoS Med  2016; 13(4)e1002009
[http://dx.doi.org/10.1371/journal.pmed.1002009] [PMID:  27046271] 
[107] 
Balmith M, Faya M, Soliman ME. Ebola virus: A gap in drug design and discovery - experimental and computational perspective. Chem Biol Drug Des  2017; 89(3): 297-308.
[http://dx.doi.org/10.1111/cbdd.12870] [PMID:  27637475] 
[108] 
Xu W, Luthra P, Wu C, et al. Ebola virus VP30 and nucleoprotein interactions modulate viral RNA synthesis. Nat Commun  2017; 8: 15576.
[http://dx.doi.org/10.1038/ncomms15576] [PMID:  28593988] 
[109] 
Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J. Ebola virus disease. Lancet  2019; 393(10174): 936-48.
[http://dx.doi.org/10.1016/S0140-6736(18)33132-5] [PMID:  30777297] 
[110] 
Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol  2013; 45(3): 331-79.
[http://dx.doi.org/10.1007/s12016-013-8368-9] [PMID:  23575961] 
[111] 
Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev  2017; 30(1): 277-319.
[http://dx.doi.org/10.1128/CMR.00010-16] [PMID:  27903593] 
[112] 
Xing Y, Proesmans M. New therapies for acute RSV infections: where are we? Eur J Pediatr  2019; 178(2): 131-8.
[http://dx.doi.org/10.1007/s00431-018-03310-7] [PMID:  30610420] 
[113] 
Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol  2019; 17(4): 233-45.
[http://dx.doi.org/10.1038/s41579-019-0149-x] [PMID:  30723301] 
[114] 
Tahamtan A, Askari FS, Bont L, Salimi V. Disease severity in respiratory syncytial virus infection: Role of host genetic variation. Rev Med Virol  2019; 29(2)e2026
[http://dx.doi.org/10.1002/rmv.2026] [PMID:  30609190] 
[115] 
Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science  2009; 326(5957): 1279-83.
[http://dx.doi.org/10.1126/science.1177634] [PMID:  19965480] 
[116] 
Cox R, Plemper RK. Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opin Drug Discov  2016; 11(6): 543-56.
[http://dx.doi.org/10.1517/17460441.2016.1174212] [PMID:  27046051] 
[117] 
Ruigrok RW, Crépin T. Nucleoproteins of negative strand RNA viruses; RNA binding, oligomerisation and binding to polymerase co-factor. Viruses  2010; 2(1): 27-32.
[http://dx.doi.org/10.3390/v2010027] [PMID:  21994598] 
[118] 
Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ  2012; 15(5): 987-96.
[http://dx.doi.org/10.3111/13696998.2012.690013] [PMID:  22574798] 
[119] 
Gilani U, Shaukat M, Rasheed A, et al. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. J Med Virol  2019; 91(1): 1-13.
[http://dx.doi.org/10.1002/jmv.25292] [PMID:  30133783] 
[120] 
Rey FA, Stiasny K, Vaney MC, Dellarole M, Heinz FX. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep  2018; 19(2): 206-24.
[http://dx.doi.org/10.15252/embr.201745302] [PMID:  29282215] 
[121] 
Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A. Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep  2015; 32(1): 29-48.
[http://dx.doi.org/10.1039/C4NP00085D] [PMID:  25315648] 
[122] 
Šebera J, Dubankova A, Sychrovský V, Ruzek D, Boura E, Nencka R. The structural model of Zika virus RNA-dependent RNA polymerase in complex with RNA for rational design of novel nucleotide inhibitors. Sci Rep  2018; 8(1): 11132.
[http://dx.doi.org/10.1038/s41598-018-29459-7] [PMID:  30042483] 
[123] 
Hassan AS, Bibby DF, Mwaringa SM, et al. Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya. PLoS One  2019; 14(2)e0210559
[http://dx.doi.org/10.1371/journal.pone.0210559] [PMID:  30759103] 
[124] 
Phillips AN, Venter F, Havlir D, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV  2019; 6(2): e116-27.
[http://dx.doi.org/10.1016/S2352-3018(18)30317-5] [PMID:  30503325] 
[125] 
Bauer L, Lyoo H, van der Schaar HM, Strating JR, van Kuppeveld FJ. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Curr Opin Virol  2017; 24: 1-8.
[http://dx.doi.org/10.1016/j.coviro.2017.03.009] [PMID:  28411509] 
[126] 
Saiz JC, Oya NJ, Blázquez AB, Escribano-Romero E, Martín-Acebes MA. Host-directed antivirals: a realistic alternative to fight zika virus. Viruses  2018; 10(9)E453
[http://dx.doi.org/10.3390/v10090453] [PMID:  30149598] 
[127] 
Shortridge MD, Wille PT, Jones AN, et al. An ultra-high affinity ligand of HIV-1 TAR reveals the RNA structure recognized by P-TEFb. Nucleic Acids Res  2019; 47(3): 1523-31.
[http://dx.doi.org/10.1093/nar/gky1197] [PMID:  30481318] 
[128] 
Quan X, Sun D, Zhou J. Molecular mechanism of HIV-1 TAT peptide and its conjugated gold nanoparticles translocating across lipid membranes. Phys Chem Chem Phys  2019; 21(20): 10300-10.
[http://dx.doi.org/10.1039/C9CP01543D] [PMID:  31070638] 
[129] 
Aguado LC, Jordan TX, Hsieh E, et al. Homologous recombination is an intrinsic defense against antiviral RNA interference. Proc Natl Acad Sci USA  2018; 115(39): E9211-9.
[http://dx.doi.org/10.1073/pnas.1810229115] [PMID:  30209219] 
[130] 
Nguyen TH, Liu X, Su ZZ, Hsu AC, Foster PS, Yang M. Potential role of micrornas in the regulation of antiviral responses to influenza infection. Front Immunol  2018; 9: 1541.
[http://dx.doi.org/10.3389/fimmu.2018.01541] [PMID:  30022983] 
[131] 
Yen PS, James A, Li JC, Chen CH, Failloux AB. Synthetic miRNAs induce dual arboviral-resistance phenotypes in the vector mosquito Aedes aegypti. Commun Biol  2018; 1: 11.
[http://dx.doi.org/10.1038/s42003-017-0011-5] [PMID:  30271898] 
[132] 
Kloc A, Rai DK, Rieder E. The roles of picornavirus untranslated regions in infection and innate immunity. Front Microbiol  2018; 9: 485.
[http://dx.doi.org/10.3389/fmicb.2018.00485] [PMID:  29616004] 
[133] 
Liao KC, Chuo V, Ng WC, et al. Identification and characterization of host proteins bound to dengue virus 3′ UTR reveal an antiviral role for quaking proteins. RNA  2018; 24(6): 803-14.
[http://dx.doi.org/10.1261/rna.064006.117] [PMID:  29572260] 
[134] 
Anasir MI, Poh CL. Structural vaccinology for viral vaccine design. Front Microbiol  2019; 10: 738.
[http://dx.doi.org/10.3389/fmicb.2019.00738] [PMID:  31040832] 
[135] 
Shameer K, Johnson KW, Readhead B. Rapid therapeutic recommendations in the context of a global public health crisis using translational bioinformatics approaches: a proof-of-concept study using nipah virus infection. bioRxiv 2018. 333021
[http://dx.doi.org/10.1101/333021] 
[136] 
Zentner I, Sierra LJ, Fraser AK, et al. Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein. ChemMedChem  2013; 8(3): 426-32.
[http://dx.doi.org/10.1002/cmdc.201200577] [PMID:  23361947] 
[137] 
Thenin-Houssier S, de Vera IM, Pedro-Rosa L, et al. Ebselen, a small-molecule capsid inhibitor of hiv-1 replication. Antimicrob Agents Chemother  2016; 60(4): 2195-208.
[http://dx.doi.org/10.1128/AAC.02574-15] [PMID:  26810656] 
[138] 
Balasubramaniam M, Zhou J, Addai A, et al. PF74 inhibits hiv-1 integration by altering the composition of the preintegration complex. J Virol  2019; 93(6): e01741-18.
[http://dx.doi.org/10.1128/JVI.01741-18] [PMID:  30567984] 
[139] 
Thenin-Houssier S, Valente ST. HIV-1 Capsid Inhibitors as Antiretroviral Agents. Curr HIV Res  2016; 14(3): 270-82.
[http://dx.doi.org/10.2174/1570162X14999160224103555] [PMID:  26957201] 
[140] 
Sancineto L, Mariotti A, Bagnoli L, et al. Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity. J Med Chem  2015; 58(24): 9601-14.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01183] [PMID:  26613134] 
[141] 
Rice WG, Turpin JA, Huang M, et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med  1997; 3(3): 341-5.
[http://dx.doi.org/10.1038/nm0397-341] [PMID:  9055865] 
[142] 
Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med  1996; 334(16): 1011-7.
[http://dx.doi.org/10.1056/NEJM199604183341602] [PMID:  8598838] 
[143] 
Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res  2007; 76(3): 203-21.
[http://dx.doi.org/10.1016/j.antiviral.2007.06.010] [PMID:  17673305] 
[144] 
Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl)  2015; 7: 95-104.
[PMID:  25897264] 
[145] 
Atta MG, De Seigneux S, Lucas GM. Clinical Pharmacology in HIV Therapy. Clin J Am Soc Nephrol  2019; 14(3): 435-44.
[http://dx.doi.org/10.2215/CJN.02240218] [PMID:  29844056] 
[146] 
Yavuz B, Morgan JL, Showalte L, Horng KR, Dandekar S, Herrera C, et al. Pharmaceutical Approaches to HIV Treatment and Prevention. Adv Ther 2018. 11800054
[http://dx.doi.org/10.1002/adtp.201800054] 
[147] 
De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol  2009; 19(5): 287-99.
[http://dx.doi.org/10.1002/rmv.624] [PMID:  19714702] 
[148] 
Pancera M, Lai YT, Bylund T, et al. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol  2017; 13(10): 1115-22.
[http://dx.doi.org/10.1038/nchembio.2460] [PMID:  28825711] 
[149] 
Yi HA, Fochtman BC, Rizzo RC, Jacobs A. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41. Curr HIV Res  2016; 14(3): 283-94.
[http://dx.doi.org/10.2174/1570162X14999160224103908] [PMID:  26957202] 
[150] 
Lu L, Yu F, Cai L, Debnath AK, Jiang S. Development of small-molecule hiv entry inhibitors specifically targeting gp120 or gp41. Curr Top Med Chem  2016; 16(10): 1074-90.
[http://dx.doi.org/10.2174/1568026615666150901114527] [PMID:  26324044] 
[151] 
Kota S, Takahashi V, Ni F, Snyder JK, Strosberg AD. Direct binding of a hepatitis C virus inhibitor to the viral capsid protein. PLoS One  2012; 7(2)e32207
[http://dx.doi.org/10.1371/journal.pone.0032207] [PMID:  22389688] 
[152] 
Lee M, Yang J, Jo E, et al. A novel inhibitor idpp interferes with entry and egress of hcv by targeting glycoprotein e1 in a genotype-specific manner. Sci Rep  2017; 7: 44676.
[http://dx.doi.org/10.1038/srep44676] [PMID:  28333153] 
[153] 
Al Olaby RR, Cocquerel L, Zemla A, et al. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One  2014; 9(10)e111333
[http://dx.doi.org/10.1371/journal.pone.0111333] [PMID:  25357246] 
[154] 
Behmard E, Abdolmaleki P, Taghdir M. Understanding the inhibitory mechanism of BIT225 drug against p7 viroporin using computational study. Biophys Chem  2018; 233: 47-54.
[http://dx.doi.org/10.1016/j.bpc.2017.11.002] [PMID:  29169687] 
[155] 
Shaw J, Fishwick CW, Harris M. Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease. Antiviral Res  2015; 117: 20-6.
[http://dx.doi.org/10.1016/j.antiviral.2015.02.005] [PMID:  25703928] 
[156] 
Jiang Y, Andrews SW, Condroski KR, et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem  2014; 57(5): 1753-69.
[http://dx.doi.org/10.1021/jm400164c] [PMID:  23672640] 
[157] 
Einav S, Sobol HD, Gehrig E, Glenn JS. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis  2010; 202(1): 65-74.
[http://dx.doi.org/10.1086/653080] [PMID:  20486856] 
[158] 
Dufner-Beattie J, O’Guin A, O’Guin S, et al. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Antimicrob Agents Chemother  2014; 58(6): 3399-410.
[http://dx.doi.org/10.1128/AAC.00113-14] [PMID:  24709254] 
[159] 
Phillips B, Cai R, Delaney W, et al. Highly potent HCV NS4B inhibitors with activity against multiple genotypes. J Med Chem  2014; 57(5): 2161-6.
[http://dx.doi.org/10.1021/jm401646w] [PMID:  24512292] 
[160] 
Li DK, Chung RT. Overview of direct-acting antiviral drugs and drug resistance of hepatitis c virus. Methods Mol Biol  2019; 1911: 3-32.
[http://dx.doi.org/10.1007/978-1-4939-8976-8_1] [PMID:  30593615] 
[161] 
Sheldon J, Barreiro P, Soriano V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs  2007; 16(8): 1171-81.
[http://dx.doi.org/10.1517/13543784.16.8.1171] [PMID:  17685867] 
[162] 
Byrd CM, Dai D, Grosenbach DW, et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother  2013; 57(1): 15-25.
[http://dx.doi.org/10.1128/AAC.01429-12] [PMID:  23070172] 
[163] 
Rausch K, Hackett BA, Weinbren NL, et al. Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus. Cell Rep  2017; 18(3): 804-15.
[http://dx.doi.org/10.1016/j.celrep.2016.12.068] [PMID:  28099856] 
[164] 
de Wispelaere M, Lian W, Potisopon S, Li PC, Jang J, Ficarro SB. Inhibition of flaviviruses by targeting a conserved pocket on the viral envelope protein. Cell Chem Biol  2018; 25(8): 1006-6. e8
[http://dx.doi.org/10.1016/j.chembiol.2018.05.011] 
[165] 
García LL, Padilla L, Castaño JC. Inhibitors compounds of the flavivirus replication process. Virol J  2017; 14(1): 95.
[http://dx.doi.org/10.1186/s12985-017-0761-1] [PMID:  28506240] 
[166] 
Li Z, Brecher M, Deng YQ, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res  2017; 27(8): 1046-64.
[http://dx.doi.org/10.1038/cr.2017.88] [PMID:  28685770] 
[167] 
Shiryaev SA, Farhy C, Pinto A, et al. Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Antiviral Res  2017; 143: 218-29.
[http://dx.doi.org/10.1016/j.antiviral.2017.04.015] [PMID:  28461069] 
[168] 
Albulescu IC, Kovacikova K, Tas A, Snijder EJ, van Hemert MJ. Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res  2017; 143: 230-6.
[http://dx.doi.org/10.1016/j.antiviral.2017.04.016] [PMID:  28461070] 
[169] 
Wang QY, Dong H, Zou B, et al. Discovery of Dengue Virus NS4B Inhibitors. J Virol  2015; 89(16): 8233-44.
[http://dx.doi.org/10.1128/JVI.00855-15] [PMID:  26018165] 
[170] 
Xie X, Zou J, Wang QY, Shi PY. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res  2015; 118: 39-45.
[http://dx.doi.org/10.1016/j.antiviral.2015.03.007] [PMID:  25796970] 
[171] 
Saiz JC, Martín-Acebes MA. The race to find antivirals for zika virus. Antimicrob Agents Chemother  2017; 61(6): e00411-7.
[http://dx.doi.org/10.1128/AAC.00411-17] [PMID:  28348160] 
[172] 
Xu HT, Hassounah SA, Colby-Germinario SP, et al. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. J Antimicrob Chemother  2017; 72(3): 727-34.
[http://dx.doi.org/10.1093/jac/dkw514] [PMID:  28069884] 
[173] 
Mottin M, Borba JVVB, Braga RC, et al. The A-Z of Zika drug discovery. Drug Discov Today  2018; 23(11): 1833-47.
[http://dx.doi.org/10.1016/j.drudis.2018.06.014] [PMID:  29935345] 
[174] 
Zhao Y, Ren J, Harlos K, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature  2016; 535(7610): 169-72.
[http://dx.doi.org/10.1038/nature18615] [PMID:  27362232] 
[175] 
Ren J, Zhao Y, Fry EE, Stuart DI. target identification and mode of action of four chemically divergent drugs against ebolavirus infection. J Med Chem  2018; 61(3): 724-33.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01249] [PMID:  29272110] 
[176] 
Basu A, Mills DM, Mitchell D, et al. Novel small molecule entry inhibitors of ebola virus. J Infect Dis  2015; 212(Suppl. 2): S425-34.
[http://dx.doi.org/10.1093/infdis/jiv223] [PMID:  26206510] 
[177] 
Yuan S. Possible FDA-approved drugs to treat Ebola virus infection. Infect Dis Poverty  2015; 4: 23.
[http://dx.doi.org/10.1186/s40249-015-0055-z] [PMID:  25984303] 
[178] 
Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res  2014; 105: 17-21.
[http://dx.doi.org/10.1016/j.antiviral.2014.02.014] [PMID:  24583123] 
[179] 
Challa S, Scott AD, Yuzhakov O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother  2015; 59(2): 1080-7.
[http://dx.doi.org/10.1128/AAC.04119-14] [PMID:  25451060] 
[180] 
DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res  2008; 77(3): 225-31.
[http://dx.doi.org/10.1016/j.antiviral.2007.11.009] [PMID:  18242722] 
[181] 
Tripp RA, Power UF, Openshaw PJM, Kauvar LM. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. J Virol  2018; 92(3): e01302-17.
[http://dx.doi.org/10.1128/JVI.01302-17] [PMID:  29118126] 
[182] 
Heylen E, Neyts J, Jochmans D. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem Pharmacol  2017; 127: 1-12.
[http://dx.doi.org/10.1016/j.bcp.2016.09.014] [PMID:  27659812] 
[183] 
Xing Y, Proesmans M. New therapies for acute RSV infections: where are we? Eur J Pediatr  2019; 178(2): 131-8.
[http://dx.doi.org/10.1007/s00431-018-03310-7] [PMID:  30610420] 
[184] 
Heylen E, Neyts J, Jochmans D. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem Pharmacol  2017; 127: 1-12.
[http://dx.doi.org/10.1016/j.bcp.2016.09.014] [PMID:  27659812] 
[185] 
Tang W, Li M, Liu Y, et al. Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane. FASEB J  2019; 33(3): 4287-99.
[http://dx.doi.org/10.1096/fj.201800579R] [PMID:  30571312] 
[186] 
Noton SL, Nagendra K, Dunn EF, Mawhorter ME, Yu Q, Fearns R. Respiratory syncytial virus inhibitor az-27 differentially inhibits different polymerase activities at the promoter. J Virol  2015; 89(15): 7786-98.
[http://dx.doi.org/10.1128/JVI.00530-15] [PMID:  25995255] 
[187] 
Fearns R, Deval J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase. Antiviral Res  2016; 134: 63-76.
[http://dx.doi.org/10.1016/j.antiviral.2016.08.006] [PMID:  27575793] 
[188] 
Lai SH, Stein DA, Guerrero-Plata A, et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther  2008; 16(6): 1120-8.
[http://dx.doi.org/10.1038/mt.2008.81] [PMID:  18443602] 
Rights & Permissions Print Cite
Article Metrics
21
4
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450119666190920153247	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
Current Drug Targets

Antiviral Drug Targets of Single-Stranded RNA Viruses Causing Chronic Human Diseases

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract
